Loading quotes...

Forecast

The analysts' average price target is €4.99 (+1,060.47%). The median is €4.99 (+1,060.47%).

Buy
  4
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Cresco Labs strengthens presence in Pennsylvania with purchase of PharmaCann for $50 million

    Cresco Labs has acquired PharmaCann Penn for $50 million, gaining nine operational medical marijuana dispensaries in Pennsylvania. The payment was made in cash and via a seller note on a debt- and cash-free basis with a normalized target working capital level. Cresco expects the transaction to boost revenue, margins and cash flow and now operates in the state as both a retail and wholesale operator, running dispensaries under the Sunnyside brand and maintaining cultivation and wholesale activities. » More on de.investing.com


  • Cresco Labs beats Q2 expectations, but stock remains under pressure

    Cresco Labs reported Q2 2026 revenue of $173.34 million and adjusted EPS of -$0.01, with both metrics topping analyst expectations. Adjusted EBITDA rose to $40 million (23% margin) and adjusted gross profit was $89 million (52% margin), while operating cash flow amounted to $15 million. The stock is trading near its 52-week low as investors weigh continued negative earnings, a only flat outlook for Q3 (around $173 million in revenue) and persistent pressures in the cannabis sector. Management sees growth potential in Pennsylvania, Ohio and Kentucky and a positive impact from possible federal reform, but warns of risks from competition, pricing pressure and regulatory uncertainty. » More on de.investing.com


  • Cresco Labs: analysts expect smaller quarterly loss on declining revenue on May 8

    Cresco Labs will report results for the quarter ended March 31, 2026, on May 8, 2026. Four analysts on average estimate a loss of -0.023 USD per share (prior year -0.060 CAD), and six analysts forecast revenue of about 148.9 million USD (prior year 237.8 million CAD). For the current fiscal year, median analyst expectations are a loss of -0.075 USD per share and revenue of about 620.8 million USD (prior year 916.4 million CAD). » More on finanzen.net


  • Cresco Labs launches at-the-market stock program for around US$100 million

    Cresco Labs has established an at-the-market (ATM) program to permit the sale of subordinate voting shares totaling up to approximately US$100 million. A distribution agreement has been entered with Haywood Securities; no shares have been issued yet. Net proceeds are intended primarily for general corporate purposes and potential acquisitions. Sales will occur on the Canadian Securities Exchange and are not registered for a U.S. public offering. » More on de.investing.com


  • Cresco Labs sells California business as part of strategic realignment

    Cresco Labs has announced the sale of its operations in California to strengthen its balance sheet and cash flow, and to focus on higher-margin core markets. CEO Charlie Bachtell cited structural challenges and price pressure in the California market as reasons for the withdrawal. Analysts see uncertain short-term growth prospects, while the company continues to distribute its premium brand FloraCal in the US. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, Cresco Labs has already paid €26.30 in dividends. The last payout was in January 2022.

Financials

In the last quarter, Cresco Labs had revenue of €152.54m and net profit of -€10.98m
(EUR) September 2026
YoY
Revenue 152.54m 8.55%
Gross profit 70.17m 3.77%
Net profit -10.98m 24.42%
EBITDA 9.14m 46.04%

Fundamentals

Metric Value
Market capitalization
€156.67m
Number of shares
361.07m
52-week high/low
€2.09 - €0.42
Dividends No
Beta
1.72
P/E ratio
-1.67
PEG ratio
0.01
P/B ratio
0.51
P/S ratio
0.26

Company profile

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

Name
Cresco Labs
CEO
Charles Bachtell
Headquarters Chicago, il
USA
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
03/12/2018
Employees 2,900

Ticker symbols

Exchange Symbol
Cnq
CL.CN
Pnk
CRLBF
Frankfurt
6CQ.F
DĂĽsseldorf
6CQ.DU
MĂĽnchen
6CQ.MU
🍪

Parqet  uses cookies. Learn more